Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.

Neurotherapeutics · 2022 · PMC8885119 · PMID 35229269

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Will tau PET ligands or other biomarkers serve as proxies for clinical efficacy? Demonstration of highly significant clinical benefit in phase 2 studies in AD is very challenging.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.